AT13148 - 98%, high purity , MAP kinase-activated protein kinase 2 inhibitor, CAS No.1056901-62-2, MAP kinase-activated protein kinase 2 inhibitor

Item Number

A413783

• Synonyms: (S)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-amino-1-(4-chlorophenyl)ethanol; SCHEMBL851471 | NCGC00386423-03 | SCHEMBL851471 | AT13148 | AT-13148 | SB16880 | AS-35164 | CS-3136 | UNII-A49037RP1E | (S)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-amino-1-(4-chlorophenyl)ethano
• Specifications & Purity: ≥98%
• Biochemical and Physiological Mechanisms: AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Action Type: INHIBITOR
• Mechanism of action: MAP kinase-activated protein kinase 2 inhibitor

Product Description

Information

AT13148 is an oral, ATP-competitive, multi-AGC kinaseinhibitor withIC50of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM forAkt1/2/3,p70S6K,PKA, andROCKI/II, respectively. Phase 1.

Targets

PKA (Cell-free assay); ROCK2 (Cell-free assay); ROCK1 (Cell-free assay); p70S6K (Cell-free assay); Akt1 (Cell-free assay) 15565,3 nM; 4 nM; 6 nM; 8 nM; 38 nM

In vitro

AT13148, as a multi-AGC kinase inhibitor, potently inhibits proliferation with GI50 values of 1.5 to 3.8 μM across a selected panel of cancer cell lines with deregulation of PI3K-AKT-mTOR or RAS-RAF pathways. In PTEN-deficient MES-SA cells, AT13148 also inhibits AKT and p70S6K signaling.

In vivo

AT13148 (50 mg/kg p.o.) markedly inhibits the activity of both AKT and p70S6K AGC kinases, and subsequently exhibits marked antitumor effects in human tumor xenografts.

Cell Research(from reference)

Cell lines：MES-SA, MES-SA/Dx5, BT474, HCT-116, A549, PC3, SK-BR-3, MCF7, U87MG, MDA-MB-468, DU-145, and SK-OV-3 cell lines 

Concentrations：~10 μM 

Incubation Time：72 hours or 96 hours